Mercy Congratulates Dr. Steven Ochs for Being Named Ohio’s First UroLift® Center of Excellence - Mercy Medical Center

Mercy Congratulates Dr. Steven Ochs for Being Named Ohio’s First UroLift® Center of Excellence

Posted on: February 15, 2018

Steven E. Ochs, M.D., a urologist at Urology One and chair of Mercy Medical Center’s Department of Surgery, performed Ohio’s first UroLift® System implant in 2015 at Mercy Medical Center. On Monday, Feb. 12, representatives from NeoTract, Inc. held a ribbon-cutting ceremony at his office to announce that Dr. Ochs is Ohio’s first to earn designation as a UroLift Center of Excellence. The designation recognizes that Dr. Ochs has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostate Hyperplasia (BPH).

“The UroLift System is a breakthrough minimally invasive treatment that provides fast, long-term relief from BPH symptoms with minimal downtime, no compromise of sexual function, and no need for continued medications,” Dr. Ochs says.

For more information about the UroLift System, visit To request an appointment with Dr. Ochs, call 330-456-6760.

“I applaud Dr. Ochs for his dedication to bring this technology to the patients in our community,” says Paul Hiltz, interim CEO at Mercy Medical Center. “UroLift is the kind of advanced treatment that can make a meaningful impact on patients’ quality of life.”

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra.

“With UroLift, we’re not removing any tissue during the procedure,” Dr. Ochs says. “We’re just compressing it.”

While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

“Most procedures for prostate enlargement have sexual side effects,” Dr. Ochs says. “This procedure has none of those.”

Akron resident Dean Testa attended the ribbon-cutting ceremony and shared his story. While traveling out-of-state for business, Testa experienced a sudden onset of symptoms. As the pain and symptoms increased, Testa visited an emergency department to seek treatment. After two hospital visits and multiple doctor appointments, Testa wasn’t getting better and says he was petrified. That’s when his sister, Darla France, a surgical nurse at Mercy Medical Center, told him about Dr. Ochs.

Testa was a good candidate for the UroLift and, in January 2017, had the procedure at Mercy Medical Center. “The relief from my symptoms was immediate,” Testa says. One year later, he continues to experience no side effects. “It is a totally different lifestyle. I don’t have to worry about getting up once, twice or three times per night. I owe a debt of gratitude to Dr. Ochs and everyone in his office.”

To learn more about Mercy Medical Center, visit our About Us page.

About the UroLift System
NeoTract’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at

About Urology One
Urology One specializes in adult and pediatric urology including treatment of prostate problems including cancer, bladder problems including cancer, kidney stones and removal, hydroceles, varicoceles, spermatoceles, erectile dysfunction, BPH, blood in urine, incontinence, recurrent UTIs, difficulty or inability to void, interstitial cycstitis and testicular/scrotal problems. Learn more at

Please click here for media inquiries

Leave a Reply

Mercy Medical Center | 1320 Mercy Drive NW, Canton, OH 44708 |
Contact Us | Careers | Privacy Policy | Copyright © 2017 Mercy Medical Center